Induction and characterization of neoplastic bladder tumors in a transgenic porcine model [0.03%]
诱导并表征转基因猪模型中的膀胱肿瘤性质及特征
Andreas Aulitzky,Viranda H Jayalath,Abraham Meyerson et al.
Andreas Aulitzky et al.
Background: Large animal models of bladder cancer are lacking. Objective: This study aimed to develop and characterize a transgenic por...
Corrigendum to "The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors" [0.03%]
“新型肾上皮细胞系HBLAK包含早期肾盂肿瘤特异性明确的基因异常”一文的勘误通知书
[This corrects the article DOI: 10.3233/BLC-160065.]. © The Author(s) 2026.
Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis [0.03%]
基于CT纹理分析的肌层浸润性膀胱癌的影像基因组学研究
Aidan Boyne,Redmond-Craig Anderson,Derek Liu et al.
Aidan Boyne et al.
Background: Urothelial bladder cancer exhibits marked molecular and clinical heterogeneity. While genomic and transcriptomic profiling of muscle-invasive bladder cancer (MIBC) has revealed recurrent alterations with thera...
Proceedings of the first international NMIBC consensus classification meeting [0.03%]
首次国际NMIBC共识分类会议纪要
Joep J de Jong,Ane Moreno-Oya,Mitchell Olislagers et al.
Joep J de Jong et al.
Non-muscle invasive bladder cancer (NMIBC) is a biologically and clinically heterogeneous disease, accounting for approximately 75% of bladder cancer cases. Over the past decade, multiple RNA-based molecular classification systems for NMIBC...
Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer [0.03%]
高级别乳头状非肌层浸润性膀胱癌患者中原位癌报告不足的现象
Adam Cole,Daniel A Shoskes,R Jonathan Henderson
Adam Cole
Background: Concomitant carcinoma in situ (CIS) with high-grade papillary urothelial carcinoma impacts patient risk stratification and treatment. However, on identification of a high-grade papillary lesion, pathologists m...
Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression [0.03%]
GALEAS膀胱扩展版的开发：尿液中FGFR3融合检测及其与基因组改变和基因表达之间的关系
Jessica L Neil,Naheema S Gordon,Anshita Goel et al.
Jessica L Neil et al.
Background: The latest bladder cancer (BC) urine tests based on multiple genomic and/or epigenomic markers detect BC with high sensitivity and specificity. The GALEAS Bladder (GB) gene panel covers several actionable muta...
A risk-adapted approach to reTURBT in high-grade T1 NMIBC [0.03%]
高危T1期非肌层浸润性膀胱癌的个体化表浅膀胱肿瘤切除（reTURBT）策略
Kamil Malshy,Edward M Messing
Kamil Malshy
Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients [0.03%]
局部肌侵袭性膀胱癌患者根治治疗的诊疗模式及其社会健康决定因素
Megan Mai,Vivie Tran,Albert Zhu et al.
Megan Mai et al.
Background: Neoadjuvant chemotherapy followed by radical cystectomy (NACT-RC) is the prevailing standard of care for muscle-invasive bladder cancer (MIBC), but trimodality treatment (TMT) using chemoradiation after transu...
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab [0.03%]
接受过一线恩fortumab vedotin与帕博利珠单抗治疗的晚期尿路上皮癌患者的二线治疗模式和结果
Georges Gebrael,Yeonjung Jo,Zeynep Irem Ozay et al.
Georges Gebrael et al.
Enfortumab vedotin with pembrolizumab (EV + pembro) has transformed first-line treatment of advanced urothelial carcinoma (aUC). No prospective data are available evaluating outcomes of different therapies following progression on EV + pemb...
Adjuvant immunotherapy for muscle-invasive urothelial carcinoma: Considerations for targeting patients [0.03%]
肌层浸润性尿路上皮癌辅助免疫治疗：患者选择考虑因素
Sarafina Urenna Otis,Aruni Ghose,Giuseppe Luigi Banna et al.
Sarafina Urenna Otis et al.
While neoadjuvant chemotherapy and radical surgery represent mainstay treatments for muscle-invasive urothelial carcinoma (MIUC), recurrence with lethal metastasis remains high and highlights the need for adjuvant therapies in MIUC, like im...